Rituximab

Grey

Brand Name(s):

Indication:refractory Focal Segmental Glomerulosclerosis in the native kidney in adults

Rationale:1

Considered:Aug-19

Review Date:Aug-24

Comments:
NHS England Policy Statement stating that no routine commissioning of this drug for this indication. This was due to a lack of clinical evidence available and availability of alternative therapies. (https://www.england.nhs.uk/wp-content/uploads/2019/07/1818-Policy-Statement)